Skip to content
Aminoscope
Head-to-head

Pterostilbene vs Resveratrol

Nearly the same molecule, with one real difference: pterostilbene is far better absorbed. What neither has is human evidence that the absorption buys anything on aging.

By Julian RothResearch & dataUpdated October 2026

Short answer

The evidence gap decides this one. Pterostilbene has human clinical data behind it, while resveratrol has only preclinical or minimal evidence, resting mostly on animal or lab work. Both are marketed for sirtuin activation and longevity, but only pterostilbene has human trial data behind that use. Both are sold over the counter as supplements.

Pterostilbene

Clinical data

Resveratrol's more-absorbable cousin — better pharmacokinetics is the real edge, but human outcome data is a couple of small trials (one raised LDL) and no aging trials exist.

Full Pterostilbene evidence review

Resveratrol

Preclinical / minimal

Spectacular in yeast and mice (SIRT1), disappointing in humans — modest benefit only in diabetics, and it blunted exercise gains in one RCT.

Full Resveratrol evidence review

Pterostilbene vs Resveratrol: head to head

FDA status / approved use

Pterostilbene

Sold as a longevity supplement ingredient, often in anti-aging stacks

Resveratrol

Sold as a longevity supplement
Marketed for

Pterostilbene

Sirtuin activation, longevity

Resveratrol

Sirtuin activation, longevity
Outcome areas

Pterostilbene

Longevity / lifespan

Resveratrol

Longevity / lifespan; Blood sugar / insulin sensitivity
Evidence grade

Pterostilbene

Clinical data

Resveratrol

Preclinical / minimal
How it works

Pterostilbene

Methylated resveratrol analog; antioxidant and sirtuin-adjacent effects in cell and animal models

Resveratrol

Proposed to activate the sirtuin SIRT1
Route and dosing

Pterostilbene

Oral; trials used 125 mg or 50 mg twice daily

Resveratrol

Oral capsule
Headline human result

Pterostilbene

High dose lowered blood pressure about 7.8/7.3 mmHg but raised LDL about 17 mg/dL as monotherapy in one small trial of 80 adults

Resveratrol

Fasting glucose about 0.29 mmol/L lower in diabetes with negligible HbA1c change (2017 meta-analysis); no effect in non-diabetics
Strongest evidence

Pterostilbene

Riche RCT, Evid Based Complement Alternat Med 2014Pterostilbene evidence reviewPubMed 25057276

Resveratrol

Human meta-analysis, AJCN 2014. Little or no controlled human outcome data for the marketed useResveratrol evidence reviewPubMed 24695890
Key safety signal

Pterostilbene

Well tolerated; raised LDL cholesterol as monotherapy; drug-enzyme interactions not characterized in people

Resveratrol

Inhibits CYP3A4, CYP2D6 and CYP2C9 at 1 g/day; GI symptoms at high doses
How it is obtained

Pterostilbene

Over the counter as a dietary supplement

Resveratrol

Over the counter as a dietary supplement

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Preclinical / minimal:
Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.

Our verdict

Resveratrol is the field's cautionary tale: spectacular in yeast and mice, modest only in people with diabetes, null in healthy people, and in one trial it blunted the cardiovascular gains of exercise training in older men. Pterostilbene fixes resveratrol's most obvious flaw, with oral bioavailability of roughly 80 percent in rats versus about 20 percent for resveratrol, but its human record is two small, short trials of metabolic markers from one research group. In that efficacy trial, high-dose monotherapy lowered blood pressure and raised LDL cholesterol by about 17 mg/dL, which is a mixed signal, not a win. The two have not been compared directly on any outcome, and neither has a single human aging trial.

Pterostilbene fits if

Pterostilbene suits the reader who wants the stilbene mechanism with pharmacokinetics that actually deliver it, and who will watch LDL while accepting there are no aging outcomes behind it.

Resveratrol fits if

Resveratrol makes sense mainly for someone with type 2 diabetes chasing the modest glucose and insulin-sensitivity signal from its meta-analyses, and not for a healthy person who trains.

Pterostilbene vs Resveratrol: common questions

Is either pterostilbene or resveratrol FDA-approved?
No. Pterostilbene is sold as a longevity supplement ingredient, often in anti-aging stacks. Resveratrol is sold as a longevity supplement.
Which has stronger human evidence, pterostilbene or resveratrol?
Pterostilbene. It has human clinical data (key source: Riche RCT, Evid Based Complement Alternat Med 2014), while resveratrol has only preclinical or minimal evidence (key source: Human meta-analysis, AJCN 2014).
What are the main safety concerns with pterostilbene and resveratrol?
Pterostilbene is well tolerated; raised LDL cholesterol as monotherapy; drug-enzyme interactions not characterized in people. Resveratrol inhibits CYP3A4, CYP2D6 and CYP2C9 at 1 g/day; GI symptoms at high doses.

Key studies behind each

Pterostilbene

  1. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. (2011). Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. PubMed 21116625
  2. McCormack D, McFadden D. (2013). A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev. PubMed 23691264
  3. Riche DM, McEwen CL, Riche KD, Sherman JJ, Wofford MR, Deschamp D, Griswold M. (2013). Analysis of safety from a human clinical trial with pterostilbene. J Toxicol. PubMed 23431291
  4. Riche DM, Riche KD, Blackshear CT, McEwen CL, Sherman JJ, Wofford MR, Griswold ME. (2014). Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med. PubMed 25057276

Resveratrol

  1. Howitz KT, Bitterman KJ, Cohen HY, et al. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. PubMed 12939617
  2. Baur JA, Pearson KJ, Price NL, et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature. PubMed 17086191
  3. Liu K, Zhou R, Wang B, Mi MT. (2014). Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. PubMed 24695890
  4. Zhu X, Wu C, Qiu S, et al. (2017). Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr Metab (Lond). PubMed 29018489

The full evidence reviews

  • Pterostilbene: resveratrol's more absorbable cousin

    Swapping two hydroxyls for methyl groups gives pterostilbene far better oral bioavailability than resveratrol — but human outcome data are two small trials, one showing a rise in LDL cholesterol, and none on aging.

    Updated August 2026

  • Resveratrol: spectacular in mice, disappointing in humans

    The 'red wine longevity molecule' extended lifespan in yeast and mice via SIRT1 — but human trials show only modest benefit in diabetics, nothing in healthy people, and it even blunted exercise gains.

    Updated August 2026